AxImmune

$1.4M revenue • 8 employees

Last Updated Jan 8, 2025

Company Overview

Company Name

AxImmune

Approx. Annual Revenue

$1.4M

Employees

8

Established

2017

About AxImmune

AxImmune Inc. is a clinical-stage immuno-oncology company developing the potent immuno-modulatory agent AX-101. Animal studies have shown that AX-101 works synergistically with immune checkpoint inhibitors, improving outcomes and potentially expanding the range of treatable cancers. The company plans to file an IND and commence clinical trials in Q4 2019.

Biotech & Life Sciences Companies near CO

Browse all Biotech & Life Sciences companies →

Frequently Asked Questions about AxImmune

Categories

Technologies Used

Key Decision Makers

Betsy Fisher Director of Outsourcing
LinkedIn